It was directed to "discover, develop and provide therapeutic solutions in [...] three major areas of research: central nervous system (CNS), cardiology and allergen immunotherapy".

[5] BIA 5-1058 is another reversible dopamine beta-hydroxylase inhibitor which decreases norepinephrine levels in peripheral sympathetically innervated tissues, without CNS effects.

[6] Opicapone (BIA 9-1067), Bial's second pharmaceutical, is a COMT inhibitor for the treatment of Parkinson disease,[7] It is under review by the European Medicines Agency (EMA).

[8] In 2015, Bial commissioned a contract research organization Biotrial to run a phase one clinical trial for BIA 10-2474, an FAAH inhibitor[9] that targets the endocannabinoid system.

[10] The research in Rennes commenced in July 2015, evaluating male and female subjects aged between 18 and 55 years old receiving a single dose.